Phenolic indeno[1,2-b]indoles as ABCG2-selective potent and non-toxic inhibitors stimulating basal ATPase activity

Ketonic indeno[1,2-b]indole-9,10-dione derivatives, initially designed as human casein kinase II (CK2) inhibitors, were recently shown to be converted into efficient inhibitors of drug efflux by the breast cancer resistance protein ABCG2 upon suited substitutions including a N5-phenethyl on C-ring and hydrophobic groups on D-ring. A series of ten phenolic and seven p-quinonic derivatives were synthesized and screened for inhibition of both CK2 and ABCG2 activities. The best phenolic inhibitors were about threefold more potent against ABCG2 than the corresponding ketonic derivatives, and showed low cytotoxicity. They were selective for ABCG2 over both P-glycoprotein and MRP1 (multidrug resistance protein 1), whereas the ketonic derivatives also interacted with MRP1, and they additionally displayed a lower interaction with CK2. Quite interestingly, they strongly stimulated ABCG2 ATPase activity, in contrast to ketonic derivatives, suggesting distinct binding sites. In contrast, the p-quinonic indenoindoles were cytotoxic and poor ABCG2 inhibitors, whereas a partial inhibition recovery could be reached upon hydrophobic substitutions on D-ring, similarly to the ketonic derivatives.

[1]  M. Schroeder The University of Göttingen , 2018, Nature.

[2]  H. Zimmer,et al.  Oxidations with potassium nitrosodisulfonate (Fremy's radical). Teuber reaction. , 1971 .

[3]  R L Juliano,et al.  A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. , 1976, Biochimica et biophysica acta.

[4]  T. Mosmann Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. , 1983, Journal of immunological methods.

[5]  M. Sainsbury,et al.  The Coupling Reactions of 3-Acylindoles and Proof of Structure of the Palladium (II) Acetane Mediated Cyclisation Reaction Product of 3-Benzoyl-1-methylindole , 1983 .

[6]  O. Issinger,et al.  Isolation and characterization of recombinant human casein kinase II subunits α and β from bacteria , 1991 .

[7]  A. Duncan,et al.  Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. , 1992, Science.

[8]  L. Doyle,et al.  A multidrug resistance transporter from human MCF-7 breast cancer cells. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[9]  Vincenzo,et al.  A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance. , 1998, Cancer research.

[10]  S. Rabindran,et al.  Reversal of a novel multidrug resistance mechanism in human colon carcinoma cells by fumitremorgin C. , 1998, Cancer research.

[11]  T. Litman,et al.  Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: demonstration of homology to ABC transport genes. , 1999, Cancer research.

[12]  T. Litman,et al.  Functional characterization of the human multidrug transporter, ABCG2, expressed in insect cells. , 2001, Biochemical and biophysical research communications.

[13]  J. Schellens,et al.  Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C. , 2002, Molecular cancer therapeutics.

[14]  M. Gottesman Mechanisms of cancer drug resistance. , 2002, Annual review of medicine.

[15]  E. Georges,et al.  A mechanism for P-glycoprotein-mediated apoptosis as revealed by verapamil hypersensitivity. , 2003, Biochemistry.

[16]  M. Gottesman,et al.  Targeting multidrug resistance in cancer , 2006, Nature Reviews Drug Discovery.

[17]  Joachim Jose,et al.  Synthesis and Biological Evaluation of 3-(Substituted-benzylidene)-1,3-dihydro-indolin Derivatives as Human Protein Kinase CK2 and p60c-Src Tyrosine Kinase Inhibitors , 2007 .

[18]  L. Szente,et al.  Membrane cholesterol selectively modulates the activity of the human ABCG2 multidrug transporter. , 2007, Biochimica et biophysica acta.

[19]  G. Sheldrick A short history of SHELX. , 2008, Acta crystallographica. Section A, Foundations of crystallography.

[20]  A. Schinkel,et al.  Physiological and pharmacological roles of ABCG2 (BCRP): recent findings in Abcg2 knockout mice. , 2009, Advanced drug delivery reviews.

[21]  M. Gottesman,et al.  Is resistance useless? Multidrug resistance and collateral sensitivity. , 2009, Trends in pharmacological sciences.

[22]  Richard J. Gildea,et al.  OLEX2: a complete structure solution, refinement and analysis program , 2009 .

[23]  H. Uno,et al.  Zosuquidar, a novel modulator of P-glycoprotein, does not improve the outcome of older patients with newly diagnosed acute myeloid leukemia: a randomized, placebo-controlled trial of the Eastern Cooperative Oncology Group 3999. , 2010, Blood.

[24]  C. Götz,et al.  A CE‐based assay for human protein kinase CK2 activity measurement and inhibitor screening , 2010, Electrophoresis.

[25]  S. Bates,et al.  The acridone derivative MBLI-87 sensitizes breast cancer resistance protein-expressing xenografts to irinotecan. , 2011, European journal of cancer.

[26]  R. Callaghan,et al.  P-glycoprotein inhibition: the past, the present and the future. , 2011, Current drug metabolism.

[27]  Veerababurao Kavala,et al.  An Easy Access to Carbazolones and 2,3-Disubstituted Indoles , 2011 .

[28]  P. Carrupt,et al.  Targeting the multidrug ABCG2 transporter with flavonoidic inhibitors: in vitro optimization and in vivo validation. , 2011, Current medicinal chemistry.

[29]  Jérôme Guitton,et al.  Substituted chromones as highly potent nontoxic inhibitors, specific for the breast cancer resistance protein. , 2012, Journal of medicinal chemistry.

[30]  F. Totzke,et al.  Novel indeno[1,2-b]indoloquinones as inhibitors of the human protein kinase CK2 with antiproliferative activity towards a broad panel of cancer cell lines. , 2012, Biochemical and biophysical research communications.

[31]  A. di Pietro,et al.  Methoxy stilbenes as potent, specific, untransported, and noncytotoxic inhibitors of breast cancer resistance protein. , 2012, ACS chemical biology.

[32]  F. Totzke,et al.  Indeno[1,2-b]indole derivatives as a novel class of potent human protein kinase CK2 inhibitors. , 2012, Bioorganic & medicinal chemistry.

[33]  Zhaohui J. Cai,et al.  Pretreatment data is highly predictive of liver chemistry signals in clinical trials , 2012, Drug design, development and therapy.

[34]  D. Ross,et al.  Role of breast cancer resistance protein (BCRP/ABCG2) in cancer drug resistance. , 2012, Biochemical pharmacology.

[35]  G. Szakács,et al.  Structure-activity relationships of chromone derivatives toward the mechanism of interaction with and inhibition of breast cancer resistance protein ABCG2. , 2013, Journal of medicinal chemistry.

[36]  J. Jose,et al.  Synthesis and biological evaluation of novel substituted pyrrolo[1,2-a]quinoxaline derivatives as inhibitors of the human protein kinase CK2. , 2013, European journal of medicinal chemistry.

[37]  A. di Pietro,et al.  Symmetric bis-chalcones as a new type of breast cancer resistance protein inhibitors with a mechanism different from that of chromones. , 2014, Journal of medicinal chemistry.

[38]  A. di Pietro,et al.  MBL-II-141, a chromone derivative, enhances irinotecan (CPT-11) anticancer efficiency in ABCG2-positive xenografts , 2014, Oncotarget.

[39]  M. Gottesman,et al.  Targeting the Achilles Heel of Multidrug-Resistant Cancer by Exploiting the Fitness Cost of Resistance , 2014, Chemical reviews.

[40]  Joachim Jose,et al.  Converting potent indeno[1,2-b]indole inhibitors of protein kinase CK2 into selective inhibitors of the breast cancer resistance protein ABCG2. , 2015, Journal of medicinal chemistry.